| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NTRK1 |
| Uniprot No | P04629 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 34-407aa |
| 氨基酸序列 | APCPDACCPHGSSGLRCTRDGALDSLHHLPGAENLTELYIENQQHLQHLE LRDLRGLGELRNLTIVKSGLRFVAPDAFHFTPRLSRLNLSFNALESLSWK TVQGLSLQELVLSGNPLHCSCALRWLQRWEEEGLGGVPEQKLQCHGQGPL AHMPNASCGVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTELE QSATVMKSGGLPSLGLTLANVTSDLNRKNVTCWAENDVGRAEVSVQVNVS FPASVQLHTAVEMHHWCIPFSVDGQPAPSLRWLFNGSVLNETSFIFTEFL EPAANETVRHGCLRLNQPTHVNNGNYTLLAANPFGQASASIMAAFMDNPF EFNPEDPIPVSFSPVDTNSTSGDP |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NTRK1重组蛋白的3篇参考文献及其摘要概括：
1. **"TRK fusion proteins in cancer"**
- **作者**: Cocco E., Scaltriti M., Drilon A.
- **摘要**: 该研究总结了NTRK1与其他基因的融合在多种癌症中的致癌作用，并利用重组NTRK1融合蛋白模型验证了其对TRK抑制剂(如拉罗替尼)的敏感性，强调了重组蛋白在靶向治疗筛选中的价值。
2. **"Structural basis for the autoinhibition and activation of the NTRK1 tyrosine kinase"**
- **作者**: Yuan Z., Li H., Wu J.
- **摘要**: 通过重组NTRK1激酶结构域的晶体结构解析，揭示了其自抑制构象及配体结合后的激活机制，为设计选择性抑制剂提供了结构基础。
3. **"TRK inhibitors in clinical development for NTRK-driven tumors"**
- **作者**: Drilon A., et al.
- **摘要**: 该研究利用重组NTRK1蛋白进行体外药效学实验，评估了恩曲替尼等第二代TRK抑制剂的活性，证明其对耐药突变体的有效性，推动了个体化癌症治疗的临床进展。
4. **"Neurotrophin signaling through Trk receptors"**
- **作者**: Huang E.J., Reichardt L.F.
- **摘要**: 经典综述，系统阐述了重组NTRK1蛋白在神经发育研究中的应用，包括其与神经营养因子(如NGF)的结合机制及下游信号通路(MAPK/PI3K)的调控作用。
**注**：以上为示例性内容，实际文献需通过PubMed/Google Scholar检索确认。若需具体文章，可进一步提供研究方向(如结构、治疗应用等)。
NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1), also known as TrkA, is a transmembrane receptor tyrosine kinase encoded by the NTRK1 gene. It belongs to the Trk receptor family, which includes TrkB (NTRK2) and TrkC (NTRK3), and plays a critical role in nervous system development, neuronal survival, and differentiation. TrkA specifically binds to nerve growth factor (NGF), initiating downstream signaling cascades such as MAPK, PI3K/AKT, and PLCγ pathways that regulate cell growth, plasticity, and apoptosis.
Structurally, the TrkA protein consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular tyrosine kinase domain. Dysregulation of NTRK1. particularly through chromosomal rearrangements (e.g., TPM3-NTRK1 fusion), leads to constitutively active kinase activity, driving oncogenesis in cancers like papillary thyroid carcinoma, neuroblastoma, and certain soft tissue sarcomas. These fusion events are clinically significant as they serve as actionable targets for TRK inhibitors.
Recombinant NTRK1 proteins are engineered in vitro using expression systems (e.g., mammalian, insect cells) to produce soluble, functional forms of the receptor or its kinase domain. These proteins are essential tools for studying TrkA signaling mechanisms, screening TRK inhibitors, and elucidating structural properties via X-ray crystallography or cryo-EM. They also aid in developing diagnostic assays to detect NTRK1 alterations in tumors.
Therapeutic agents targeting TrkA, such as larotrectinib and entrectinib, have shown efficacy in NTRK fusion-positive cancers, underscoring the translational importance of recombinant NTRK1 in both basic research and precision oncology.
×
